- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe chronic plaque psoriasis
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 316KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 52KB)
Risankizumab – November 2021
Risankizumab: Injection 150mg in 1 mL pre-filled pen, Injection 150mg in 1 mL pre-filled syringe; Skyrizi®
Last updated
4 March 2022